DNA

Johnson & Johnson celebrates innovation in cancer research with 2025 Dr. Paul Janssen Award

Tony Hunter, Ph.D., celebrated for pioneering discoveries that inspired the development of more than 80 cancer therapies that continue to…

5 days ago

Factorial Biotechnologies and Honeycomb Biotechnologies Partner to Deliver High-Throughput, Instrument-Free Single-Cell DNA Sequencing

New partnership combines Factorial's in-cell library preparation chemistry with Honeycomb's HIVE™ platform to enable scalable single-cell WGS workflow with processing…

5 days ago

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy…

5 days ago

Illumina and PREMIA partner to expand clinical access to CGP in Asia

TAIPEI, Taiwan, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Illumina Taiwan Biotechnology Co., Ltd., and Precision Medicine Asia, Limited (PREMIA), a…

5 days ago

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D.,…

5 days ago

Recludix Pharma Bolsters Scientific Advisory Board with Acclaimed Leaders in the Fields of Rheumatology, Dermatology and JAK/STAT Biology

SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors…

5 days ago

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in…

5 days ago

4DMT Provides Company Update and Anticipated Development Milestones for 2026

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in…

6 days ago

Artios to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, United Kingdom and NEW YORK, January 7, 2026 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing…

6 days ago

Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a…

6 days ago